AstraZeneca appeals attorneys' fees ruling in Prilosec OTC patent case
This article was originally published in Scrip
Executive Summary
AstraZeneca is appealing against a US District Court ruling that could see the company pay out more than $500,000 in attorneys' fees and costs to Dr Reddy's Laboratories (DRL) following a failed attempt to block the Indian company's generic version of heartburn remedy Prilosec OTC (omeprazole).